Cargando…
Refining patient selection for breast cancer immunotherapy: beyond PD-L1
Therapies that modulate immune response to cancer, such as immune checkpoint inhibitors, began an intense development a few years ago; however, in breast cancer (BC), the results have been relatively disappointing so far. Finding biomarkers for better selection of BC patients for various immunothera...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426207/ https://www.ncbi.nlm.nih.gov/pubmed/34487970 http://dx.doi.org/10.1016/j.esmoop.2021.100257 |